Findings

What do systematic reviews say?

7 questions · 7 findings · 6 reviews · Oral medicine and oral cancer

No studies found 5 · 71.4%GRADE not reported 2 · 28.6%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found

Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
The trials did not measure costs.
0 studies
No studies found

Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported

Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found

Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
No trial reported this planned secondary outcome for any comparison in this review
Studies not reported
No studies found

Cost (mean per-patient supportive care costs) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
Mean per-patient supportive care costs lower with amifostine (USD 4401) than control (USD 5873); P = 0.02 (Buntzel 1998 / Bennett 2001)
1 study · 28 participants
GRADE not reported

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
0 studies
No studies found